CN104435384B - A kind of anti-inflammation slow releasing tablet - Google Patents
A kind of anti-inflammation slow releasing tablet Download PDFInfo
- Publication number
- CN104435384B CN104435384B CN201410705162.5A CN201410705162A CN104435384B CN 104435384 B CN104435384 B CN 104435384B CN 201410705162 A CN201410705162 A CN 201410705162A CN 104435384 B CN104435384 B CN 104435384B
- Authority
- CN
- China
- Prior art keywords
- slow releasing
- hypromellose
- callicarpa nudiflora
- releasing tablet
- inflammation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of anti-inflammation slow releasing preparation about Callicarpa nudiflora and preparation method thereof.Described slow releasing tablet, its by percentage by weight be the Callicarpa nudiflora extract of 30% ~ 50%, framework material, the filler of 10% ~ 40%, the porogen of double taste masking of 10% ~ 30% and the lubricant of 0.5% ~ 1.5% of 15% ~ 35% form.Described framework material is preferably the mixture of hypromellose or hypromellose, carbomer and ethyl cellulose, and in described mixture, the mass ratio of hypromellose, carbomer and ethyl cellulose is 10:3 ~ 5:1 ~ 2.Described filler is preferably lactose or microcrystalline Cellulose; The preferred Polyethylene Glycol of described porogen; Described lubricant is preferably micropowder silica gel.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, be specifically related to a kind of anti-inflammation slow releasing preparation about Callicarpa nudiflora and preparation method thereof.
Background technology
Callicarpa nudiflora (CallicarpanudifloraHook.etArn.) is Verenaceae (Verbenaceae) Callicarpa plant, and main product is in China Hainan, and be a kind of Hainan authentic medicinal herbs, also there is distribution in China Guangdong, Guangxi.There are some researches show that the main component of Callicarpa nudiflora medical material is flavonoid, tannin, terpenoid, volatile oil etc. at present, wherein terpenoid and flavone can increase hematoblastic quantity, shorten hemorrhage and clotting time, to fibrinolytic system, there is significant inhibitory action, vasoconstrictive, haemostatic effect are remarkable, to inflammation early stage ooze out, swelling has obvious inhibitory action, accelerate the absorption that wound surface oozes out, promote the healing of wound, all have stronger bacteriostasis to staphylococcus aureus, salmonella typhi, Diplococcus pneumoniae, bacillus pyocyaneus etc.; And tannin can make the blood capillary of wound surface shrink, there is local hemostasis effect.Be usually used in the inflammation that treatment bacteriological infection causes clinically, acute infectious hepatitis, the diseases such as digestive tract hemorrhage.
The dosage form of current Callicarpa nudiflora has conventional tablet and capsule, and has listed national drug ministry standard in.But ordinary preparation administration is frequent, and need to take 3 day, each 2 ~ 3, patient compliance is poor, and blood concentration fluctuation is large, and long term administration easily causes untoward reaction.
Slow releasing preparation (sustainedreleasepreparation) refers to by suitable method, delay the processes such as medicine release in vivo, absorption, distribution, metabolism and excretion, thus reach a class preparation of the objects such as prolong drug effect, minimizing toxic and side effects.Its " peak valley " phenomenon that ordinary preparation frequent drug administration can be avoided to occur, makes Drug safety, effectiveness and adaptability increase.The current complicated component due to Chinese medicine extract, Sustained Release Preparations of Chinese Medicinal also exists adjuvant screening difficulty in preparation, the technical problems such as forming technology difference and drug releasing rate instability.
Summary of the invention
For the series of problems that current prior art exists, an object of the present invention is to provide a kind of release and stablize lasting slow releasing tablet, its by percentage by weight be the Callicarpa nudiflora extract of 30% ~ 50%, framework material, the filler of 10% ~ 40%, the porogen of double taste masking of 10% ~ 30% and the lubricant of 0.5% ~ 1.5% of 15% ~ 35% form.
In the present invention further embodiment, described slow releasing tablet, its weight ratio be preferably 35% ~ 45% Callicarpa nudiflora extract, the framework material of 20% ~ 30%, the filler of 20% ~ 30% and 10% ~ 20% double taste masking porogen and 0.5% lubricant composition.
In the present invention further embodiment, described framework material is one of hypromellose, ethyl cellulose, cellulose acetate, carbomer or their mixture.Described filler is microcrystalline Cellulose, lactose, calcium hydrogen phosphate, starch or their mixture.Described porogen is mannitol, sorbitol, Polyethylene Glycol or glucose.Described lubricant is Pulvis Talci, micropowder silica gel or magnesium stearate.
In the present invention further embodiment, described framework material is preferably the mixture of hypromellose or hypromellose, carbomer and ethyl cellulose, the model of described hypromellose can be K4M, K15M or K100M, be preferably the mixture of K4M or K4M and K100M, in the mixture of K4M and K100M, K4M:K100M is 9:1.Described carbomer model is preferably 971P.In described mixture, the mass ratio of hypromellose, carbomer and ethyl cellulose is 10:3 ~ 5:1 ~ 2, is preferably 10:4:1.5.Described filler is preferably lactose or microcrystalline Cellulose; The preferred Polyethylene Glycol of described porogen, is more preferably Macrogol 4000; Described lubricant is preferably micropowder silica gel.
In the present invention, described Callicarpa nudiflora extract can obtain by prior art, such as, and the preparation method of Callicarpa nudiflora extract disclosed in patent documentation CN102205000A, but be not limited thereto method.
Another object of the present invention is to provide a kind of method preparing above-mentioned slow releasing preparation, the mixing of the framework material of corresponding proportioning, filler and porogen is added to Callicarpa nudiflora extract, spray into ethanol in proper amount or ethanol water carries out wet granulation, dry, granulate, add lubricant mixing, tabletting and get final product.
In embodiment further, described ethanol water is preferably 60% alcoholic solution.
The present invention is directed to the relevant feature of Callicarpa nudiflora extract, select suitable relevant auxiliary materials, thus obtain that a kind of moulding process is good, good stability and the stable Callicarpa nudiflora slow releasing preparation of drug releasing rate.
Accompanying drawing explanation
Accompanying drawing 1: the blood drug level after slow releasing tablet prepared by Oral Administration in Rats embodiment 1-5
Detailed description of the invention
Further will describe the present invention in detail by way of example below.It is pointed out that following explanation is only illustrating the technical scheme that application claims is protected, any restriction not to these technical schemes.The content that protection scope of the present invention is recorded with appended claims is as the criterion.
Embodiment 1
Adopt preparation method disclosed in patent documentation CN102205000A to prepare Callicarpa nudiflora extract, below all with.
Concrete grammar is as follows: 1) Callicarpa nudiflora grinding medicinal materials 7-9 times amount concentration is 70-90% soak with ethanol 60-90min, 30-50min is extracted afterwards with ultrasonic extractor, then filter, it is 70-90% soak with ethanol 60-90min that filtering residue adds 3-5 times amount concentration again, 15-25min is extracted afterwards with ultrasonic extractor, filter and merge twice filtrate, 1. the ethanol reclaimed in filtrate obtain extractum;
2) filtering residue crossed of above-mentioned ethanol extraction again with 8-12 times of water gaging for solvent, extract 30-50min with ultrasonic extractor, filter afterwards, aqueous extract after concentrating under reduced pressure extractum 2.;
3) merge extractum 1. with extractum 2., reduced under vacuum becomes thick paste, by thick paste dry to moisture below 5%, obtain Callicarpa nudiflora extract.
Spray into ethanol in proper amount aqueous solution (60%) and carry out wet granulation, dry, granulate, adds magnesium stearate lubricant 50g and mixes, tabletting and get final product.
Embodiment 2
Technique is with embodiment 1.
Embodiment 3
Technique is with embodiment 1.
Embodiment 4
Technique is with embodiment 1.
Embodiment 5
Technique is with embodiment 1.
Embodiment 6 weight differential and friability inspection
According to the pertinent regulations of tablet weight variation inspection technique (Chinese Pharmacopoeia 2010 editions annex IA), determine the limit test of weight variation of this product.Result is as follows:
| Average sheet heavy (g) | Diversity factor (%) | |
| Embodiment 1 | 0.301 | ±3.6 |
| Embodiment 2 | 0.313 | ±1.5 |
| Embodiment 3 | 0.308 | ±1.3 |
| Embodiment 4 | 0.305 | ±3.9 |
| Embodiment 5 | 0.311 | ±2.2 |
According to tablet friability inspection technique (Chinese Pharmacopoeia 2010 editions annex XG), slow releasing tablet is put into cylinder and rotate 100 times, take out precise weighing, observe slow releasing tablet outward appearance.
| Friability (%) | Outward appearance | |
| Embodiment 1 | 0.5 | The sheet not detecting fracture, be full of cracks and pulverize |
| Embodiment 2 | 0.2 | The sheet not detecting fracture, be full of cracks and pulverize |
| Embodiment 3 | 0.1 | The sheet not detecting fracture, be full of cracks and pulverize |
| Embodiment 4 | 0.4 | The sheet not detecting fracture, be full of cracks and pulverize |
| Embodiment 5 | 0.3 | The sheet not detecting fracture, be full of cracks and pulverize |
Embodiment 7 sustained-release tablets is tested
Release medium, for imitating human gastrointestinal tract environment (being 0.1mol/L hydrochloric acid before 2h, is the PBS buffer of pH6.8 after 2h), investigates the release of slow releasing tablet prepared by each embodiment respectively.
Release investigation method: the content first being measured ursolic acid and luteolin in slow releasing tablet by HPLC, then release medium will be put into lot number slow releasing tablet and investigate release.
Result is as follows:
Embodiment 1
Embodiment 2
Embodiment 3
Embodiment 4
Embodiment 5
The release research in rat body of embodiment 8 slow releasing tablet
With reference to non-patent literature: the Internal pharmacokinetics research of luteolin after Oral Administration in Rats Callicarpa nudiflora, Li Ling's Na etc., Hainan Medical College's journal, slow releasing tablet prepared by the 2012. couples of embodiment 1-5 carries out pharmacokinetic (dosage is 500mg/kg).Concrete outcome is see accompanying drawing 1.
Result as can be seen from accompanying drawing, not very stable in drug release process in slow releasing tablet prepared by embodiment 1,4 and 5, significantly prominent phenomenon of releasing is had to occur, and slow releasing tablet drug release rate prepared by embodiment 2 and 3 is comparatively steady, obvious content of luteolin (2-3 μ g/ml) still can be detected after 24 hours in blood.
Content of the present invention merely illustrates some claimed specific embodiments; one of them or more described technical characteristic can be combined with arbitrary one or more technical scheme in technical scheme; these technical schemes obtained through combination also in the application's protection domain, just as these technical schemes obtained through combination in the disclosure of invention concrete record.
Claims (1)
1. the slow releasing tablet of an anti-inflammation, it is characterized in that, it is made up of the micropowder silica gel of the ethyl cellulose of the CARBOPOL 971 of the Callicarpa nudiflora extract of 400g, the HPMC K4M of 145g, hypromellose K100M, 65g of 16g, 24g, the microcrystalline Cellulose of 200g, the Macrogol 4000 of 100g and 50g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410705162.5A CN104435384B (en) | 2014-11-27 | 2014-11-27 | A kind of anti-inflammation slow releasing tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410705162.5A CN104435384B (en) | 2014-11-27 | 2014-11-27 | A kind of anti-inflammation slow releasing tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104435384A CN104435384A (en) | 2015-03-25 |
| CN104435384B true CN104435384B (en) | 2016-01-13 |
Family
ID=52882645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410705162.5A Active CN104435384B (en) | 2014-11-27 | 2014-11-27 | A kind of anti-inflammation slow releasing tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435384B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848728A (en) * | 2022-03-31 | 2022-08-05 | 广东梅州职业技术学院 | Skeleton type beautyberry slow-release granule and preparation method and application thereof |
| CN114788846A (en) * | 2022-04-08 | 2022-07-26 | 广东梅州职业技术学院 | Callicarpa kwangsiensis compound preparation and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672705A (en) * | 2004-03-25 | 2005-09-28 | 一笑堂（湖南）制药有限公司 | Dispersive tablet of nudiflorus Taiwan beautyberry leaf and its prepn |
-
2014
- 2014-11-27 CN CN201410705162.5A patent/CN104435384B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1672705A (en) * | 2004-03-25 | 2005-09-28 | 一笑堂（湖南）制药有限公司 | Dispersive tablet of nudiflorus Taiwan beautyberry leaf and its prepn |
Non-Patent Citations (1)
| Title |
|---|
| 《缓释片剂的研究概况》;徐济恒等;《安徽化工》;20110228;第37卷(第1期);27-29 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104435384A (en) | 2015-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101099729B (en) | Oral solid preparation containing ambroxol hydrochloride and salbutamol active components | |
| CN101888834A (en) | Oral dispersable tablet | |
| CN102512393A (en) | Oral disintegrated tablet containing tolvaptan | |
| CN101869633B (en) | Enteric-coated medicament combination containing epigallocatechin gallate | |
| CN105456270A (en) | Dipeptidyl peptidase IV inhibitor pharmaceutical composition, use and preparation method thereof | |
| MX2012012459A (en) | Orally disintegrating tablet containing acarbose. | |
| CN104435384B (en) | A kind of anti-inflammation slow releasing tablet | |
| CN103251844B (en) | For the tablet of cleaning throat and moistening larynx | |
| CN102441019B (en) | Chinese medicinal chrysanthemum buccal tablet | |
| CN101099730A (en) | Oral solid preparation containing ambroxol hydrochloride and guaifenesin active components | |
| CN103120652A (en) | Phloroglucin orally disintegrating tablet and preparation method thereof | |
| CN103127198B (en) | Combined drug for treating piglet's yellow-white dysentery | |
| CN1895535A (en) | Chinese-medicinal preparation for treating gutture disease and it making method | |
| CN101229141A (en) | Aspirin sustained release tablet and preparing method thereof | |
| CN103494792B (en) | Compound phloroglucinol freeze-dried orally-disintegrating tablet and preparation method | |
| CN103169681B (en) | Dimemorfan phosphate tablet composite and preparation method thereof | |
| US20110091536A1 (en) | Compositions comprising euphorbia prostrata and process of preparation thereof | |
| US20110142944A1 (en) | Andrographis extract formulations | |
| CN103463453B (en) | A kind of Dendrobium nobile tablet and preparation method thereof | |
| CN105030707A (en) | Method for preparing clotrimazole buccal tablets on basis of all-powder direct pressing of modified glucose | |
| CN101874792B (en) | Phloroglucinol orally disintegrating tablets and preparation method thereof | |
| CN101756946A (en) | Oral solid preparation for treating chronic bronchitis | |
| KR102305932B1 (en) | Solid pharmaceutical composition of brown algae | |
| CN102772455A (en) | Seabuckthorn flavone dispersible tablets | |
| CN102961380A (en) | Pharmaceutical composition for treating acute lung injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 343100 No. 5 Ji'an Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: Puzheng Pharmaceutical Group Co., Ltd. Address before: 343100 Puzheng Pharmaceutical Co., Ltd. Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee before: Puzheng Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: 343100 Innovation Avenue 278, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee after: Jiangxi Puzheng Pharmaceutical Co., Ltd. Address before: 343100 No. 5 Ji'an Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an City, Jiangxi Province Patentee before: PUZHENG PHARMACEUTICAL GROUP Co.,Ltd. |